DK2534242T3 - Improved composition for the inhibition of tumor cell proliferation - Google Patents

Improved composition for the inhibition of tumor cell proliferation Download PDF

Info

Publication number
DK2534242T3
DK2534242T3 DK11702471.1T DK11702471T DK2534242T3 DK 2534242 T3 DK2534242 T3 DK 2534242T3 DK 11702471 T DK11702471 T DK 11702471T DK 2534242 T3 DK2534242 T3 DK 2534242T3
Authority
DK
Denmark
Prior art keywords
cells
tumor
mature
dcs
cancer
Prior art date
Application number
DK11702471.1T
Other languages
Danish (da)
English (en)
Inventor
Alex Karlsson-Parra
Bengt Andersson
Annacarin Wallgren
Original Assignee
Immunicum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunicum Ab filed Critical Immunicum Ab
Application granted granted Critical
Publication of DK2534242T3 publication Critical patent/DK2534242T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A61K40/4532—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK11702471.1T 2010-02-10 2011-02-10 Improved composition for the inhibition of tumor cell proliferation DK2534242T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30315310P 2010-02-10 2010-02-10
SE1050133 2010-02-10
PCT/EP2011/051952 WO2011098516A1 (en) 2010-02-10 2011-02-10 Improved composition for inhibiting tumor cell proliferation

Publications (1)

Publication Number Publication Date
DK2534242T3 true DK2534242T3 (en) 2016-07-18

Family

ID=43903832

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11702471.1T DK2534242T3 (en) 2010-02-10 2011-02-10 Improved composition for the inhibition of tumor cell proliferation

Country Status (13)

Country Link
US (1) US9034317B2 (enExample)
EP (1) EP2534242B1 (enExample)
JP (1) JP5855018B2 (enExample)
KR (1) KR101770785B1 (enExample)
CN (1) CN102782123B (enExample)
BR (1) BR112012019267B1 (enExample)
DK (1) DK2534242T3 (enExample)
ES (1) ES2581277T3 (enExample)
HU (1) HUE028352T2 (enExample)
PL (1) PL2534242T3 (enExample)
RU (1) RU2565542C2 (enExample)
SI (1) SI2534242T1 (enExample)
WO (1) WO2011098516A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2591230T3 (es) 2012-12-18 2016-11-25 Immunicum Ab Co-diferenciación y activación de monocitos procedentes de donantes alogénicos para producir células dendríticas pro-inflamatorias
AU2016259020B2 (en) * 2015-05-07 2021-12-09 Baylor College Of Medicine Dendritic cell immunotherapy
CN105695403A (zh) * 2015-12-31 2016-06-22 深圳市中美康士生物科技有限公司 一种杀伤性免疫细胞的培养方法及其应用
CN105462926A (zh) * 2015-12-31 2016-04-06 深圳市中美康士生物科技有限公司 一种免疫细胞瘤苗的制备方法及其应用
CN107574149B (zh) * 2016-07-05 2022-02-18 上海细胞治疗研究院 一种树突状细胞的促成熟方法及其用途
CN106085960A (zh) * 2016-07-28 2016-11-09 广州赛莱拉干细胞科技股份有限公司 一种培养dc细胞的培养基及培养方法
CA3037882A1 (en) * 2016-09-23 2018-03-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
GB201711379D0 (en) 2017-07-14 2017-08-30 Univ Cape Town Maturation of dendritic cells
SI3460052T1 (sl) * 2017-09-20 2020-03-31 Immunicum Ab Izboljšane alogene dendritične celice za uporabo pri zdravljenju raka

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040214783A1 (en) * 2002-05-08 2004-10-28 Terman David S. Compositions and methods for treatment of neoplastic disease
WO2004053072A2 (en) * 2002-12-06 2004-06-24 Northwest Biotherapeutics, Inc. Administration of dendritic cells partially matured in vitro for the treatment of tumors
EP1840206A1 (en) * 2006-03-28 2007-10-03 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Compositions for the preparation of mature dendritic cells
WO2008110569A1 (en) 2007-03-12 2008-09-18 Bioneer A/S Method for determination of immunomodulatory effect
CN101883845B (zh) 2007-10-08 2015-06-10 英特瑞克斯顿股份有限公司 工程树突细胞及其在癌症治疗中的应用
WO2010065876A2 (en) * 2008-12-06 2010-06-10 The Board Of Regents Of The University Of Texas System Methods and compositions related to th-1 dendritic cells
CN101481677B (zh) * 2009-01-22 2011-12-14 复旦大学附属华山医院 体外刺激树突状细胞成熟的方法

Also Published As

Publication number Publication date
EP2534242A1 (en) 2012-12-19
WO2011098516A1 (en) 2011-08-18
RU2565542C2 (ru) 2015-10-20
PL2534242T3 (pl) 2016-11-30
US20120328662A1 (en) 2012-12-27
BR112012019267A2 (pt) 2020-10-06
HUE028352T2 (en) 2016-12-28
JP5855018B2 (ja) 2016-02-09
CN102782123A (zh) 2012-11-14
SI2534242T1 (sl) 2016-08-31
CN102782123B (zh) 2016-05-11
KR20120114358A (ko) 2012-10-16
BR112012019267B1 (pt) 2022-03-03
KR101770785B1 (ko) 2017-08-23
ES2581277T3 (es) 2016-09-05
JP2013519363A (ja) 2013-05-30
US9034317B2 (en) 2015-05-19
EP2534242B1 (en) 2016-04-20
RU2012137173A (ru) 2014-03-20

Similar Documents

Publication Publication Date Title
DK2534242T3 (en) Improved composition for the inhibition of tumor cell proliferation
Xu et al. Nanovaccine based on a protein-delivering dendrimer for effective antigen cross-presentation and cancer immunotherapy
Liau et al. Treatment of intracranial gliomas with bone marrow—derived dendritic cells pulsed with tumor antigens
EP3460052B1 (en) Improved allogeneic dendritic cells for use in cancer treatment
KR20140043340A (ko) T 세포의 프라이밍을 위한 방법
KR20120093978A (ko) 항원 특이적 ｔ 세포의 증식 방법
US12220451B2 (en) Cell-based vaccine compositions and methods of use
AU2008265911A1 (en) Use of TLR agonists and/or type 1 interferons to alleviate toxicity of TNF-R agonist therapeutic regimens
JP2018535191A (ja) 樹状細胞を産生するための組成物及び方法
JP7146732B2 (ja) 宿主抗原提示並びに宿主抗腫瘍及び抗病原体免疫を最適化するためのプラットフォーム及び方法
ES2927913B2 (es) Composición que comprende una combinación de las furanocumarinas psoraleno y angelicina y su uso en terapia
US10716810B2 (en) Canine autologous immunotherapy using dendritic cell induced cancer killing immunocytes
WO2016135286A1 (en) Method for stimulating dendritic cells (dcs)
Su Design of Immunoactive Biomaterials for Therapeutic Applications
HK40018462A (en) Improved allogeneic dendritic cells for use in cancer treatment
Ishii et al. Application of NKT Cells in Immunotherapy
Obermoser et al. Dendritic cells in SLE
AU2008280436A1 (en) Compositions and methods for generating an immune response in a subject